448 related articles for article (PubMed ID: 27569432)
1. Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm.
Halpern JA; Shoag JE; Mittal S; Oromendia C; Ballman KV; Hershman DL; Wright JD; Shih YT; Nguyen PL; Hu JC
J Urol; 2017 Feb; 197(2):363-368. PubMed ID: 27569432
[TBL] [Abstract][Full Text] [Related]
2. Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer.
Halpern JA; Oromendia C; Shoag JE; Mittal S; Cosiano MF; Ballman KV; Vickers AJ; Hu JC
J Urol; 2018 Apr; 199(4):947-953. PubMed ID: 29061540
[TBL] [Abstract][Full Text] [Related]
3. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
[TBL] [Abstract][Full Text] [Related]
5. Decline in Prostate Cancer Screening by Primary Care Physicians: An Analysis of Trends in the Use of Digital Rectal Examination and Prostate Specific Antigen Testing.
Shoag J; Halpern JA; Lee DJ; Mittal S; Ballman KV; Barbieri CE; Hu JC
J Urol; 2016 Oct; 196(4):1047-52. PubMed ID: 27060052
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men.
Catalona WJ; Richie JP; Ahmann FR; Hudson MA; Scardino PT; Flanigan RC; DeKernion JB; Ratliff TL; Kavoussi LR; Dalkin BL; Waters WB; MacFarlane MT; Southwick PC
J Urol; 2017 Feb; 197(2S):S200-S207. PubMed ID: 28012755
[TBL] [Abstract][Full Text] [Related]
7. Lethal Prostate Cancer in the PLCO Cancer Screening Trial.
Shoag J; Mittal S; Halpern JA; Scherr D; Hu JC; Barbieri CE
Eur Urol; 2016 Jul; 70(1):2-5. PubMed ID: 27166670
[TBL] [Abstract][Full Text] [Related]
8. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
9. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
[TBL] [Abstract][Full Text] [Related]
10. The digital rectal examination (DRE) remains important - outcomes from a contemporary cohort of men undergoing an initial 12-18 core prostate needle biopsy.
Palmerola R; Smith P; Elliot V; Reese CT; Mahon FB; Harpster LE; Icitovic N; Raman JD
Can J Urol; 2012 Dec; 19(6):6542-7. PubMed ID: 23228289
[TBL] [Abstract][Full Text] [Related]
11. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Pinsky PF; Black A; Parnes HL; Grubb R; David Crawford E; Miller A; Reding D; Andriole G
Cancer Epidemiol; 2012 Dec; 36(6):e401-6. PubMed ID: 23000116
[TBL] [Abstract][Full Text] [Related]
13. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.
Pinsky PF; Prorok PC; Yu K; Kramer BS; Black A; Gohagan JK; Crawford ED; Grubb RL; Andriole GL
Cancer; 2017 Feb; 123(4):592-599. PubMed ID: 27911486
[TBL] [Abstract][Full Text] [Related]
14. Mortality results from a randomized prostate-cancer screening trial.
Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Gelmann EP; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Clapp JD; Rathmell JM; Riley TL; Hayes RB; Kramer BS; Izmirlian G; Miller AB; Pinsky PF; Prorok PC; Gohagan JK; Berg CD;
N Engl J Med; 2009 Mar; 360(13):1310-9. PubMed ID: 19297565
[TBL] [Abstract][Full Text] [Related]
15. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
Thompson IM; Tangen CM; Goodman PJ; Lucia MS; Parnes HL; Lippman SM; Coltman CA
J Urol; 2007 May; 177(5):1749-52. PubMed ID: 17437804
[TBL] [Abstract][Full Text] [Related]
16. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
17. Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial.
Pinsky PF; Miller E; Prorok P; Grubb R; Crawford ED; Andriole G
BJU Int; 2019 May; 123(5):854-860. PubMed ID: 30288918
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation on the effect of interobserver variability of digital rectal examination on the performance of the Rotterdam Prostate Cancer Risk Calculator.
Pereira-Azevedo N; Braga I; Verbeek JF; Osório L; Cavadas V; Fraga A; Carrasquinho E; Cardoso de Oliveira E; Nieboer D; Roobol MJ
Int J Urol; 2017 Dec; 24(12):826-832. PubMed ID: 28901582
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
[TBL] [Abstract][Full Text] [Related]
20. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.
Pinsky PF; Andriole GL; Kramer BS; Hayes RB; Prorok PC; Gohagan JK;
J Urol; 2005 Mar; 173(3):746-50; discussion 750-1. PubMed ID: 15711261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]